Our Journey

Imexpharm, the domestic pharmaceutical company, owns the most EU-GMP lines in Vietnam

In September 2022, Binh Duong Hi-tech Factory (IMP4) was officially certified to meet EU-GMP standards, for a total number of 11 EU-GMP production lines to place Imexpharm at the No.1 position in this regard in Vietnam. Also in 2022, a visa to export to European market was granted to 3 additional products, including Cephalexin 250 mg oral suspension, Pantoprazole 40mg lyophilized injection, and Cefixime 200mg film-coated tablets, for a total number of 7 products to enter European market (with 12 registration numbers).
This was also a turning point in its operations. SK Group (South Korea) undertook to increase its investment in Imexpharm to facilitate its “global reach” journey.

Provide comprehensive health solutions. Proud Vietnamese drug brand international integration.

In 2021, the Company put into commercial operation its Supplement Factory as part of its head office in Cao Lanh City, Dong Thap province following an investment of VND 82 billion. Also in 2021, Imexpharm successfully registered European Visa for 2 products: Amoxicillin 250 mg oral suspension and Amoxicillin 500 mg capsules, and successfully demonstrated the “bioequivalence” of two products, Zanimex 500mg film-coated tablets and Biocemet DT 500mg/62.5mg dispersible tablets. From this foundation, Imexpharm has firmly made a breakthrough towards exporting high-quality products to fastidious markets.

In 2020, Imexpharm obtained a European conformity certification for Cefalexin 500 mg capsules. It is important to note that, during this period, Imexpharm’s efforts were backed by international partners and investors. In 2020, SK Group (South Korea) became one of its strategic shareholders and participated in its governance. The Asian Development Bank (ADB) conducted an operational appraisal and provided a loan worth USD 8 million, on a ground of Imexpharm’s transparent, robust, and reliable development.

IMP4 Hi-tech Factory inaugurated in 2019 with an investment capital of 470 billion VND

IMP4 Hi-Tech Factory - Binh Duong was inaugurated in 2019 with an investment of 470 billion VND. The factory is considered the golden star of Imexpharm so far. The factory qualified for WHO-GMP in July 2019. Besides, The High-tech antibiotic factory IMP2 - Vinh Loc: September 2018 The Portuguese Ministry of Health approved the factory according to EU-GMP standards. On 02/01/2019 received this certificate.

Nhà máy IMP 2 được bộ y tế xét duyệt và cấp giấy chứng nhận WHO-GMP

Đầu năm 2018 nhà máy IMP2 đi vào hoạt động. Tháng 03/2018 Bộ Y tế Việt Nam vào xét để cấp chứng nhận WHO-GMP, GLP, GSP. Tháng 04/2018 nhà máy nhận được các chứng nhận này. Imexpharm bắt đầu khởi công nhà máy IMP 4 Bình Dương với vốn đầu tư 470 tỷ đồng.

Nhà máy Kháng sinh Công nghệ cao IMP2 được hoàn thành vào tháng 10 năm 2017.

Sản phẩm đầu tiên nhận Visa Châu Âu của Imexpharm.

Tháng 10/ 2017 nhà máy IMP2 được xây dựng xong, các thiết bị, hệ thống phụ trợ lắp đặt hoàn thiện. Từ tháng 11/ 2017 dự kiến đến tháng 02/2018 đưa nhà máy vào hoạt động thẩm định (chạy thử). Nhà máy Kháng sinh Công nghệ cao IMP2 - Vĩnh Lộc có vốn đầu tư 180 tỷ đồng. Chuyên Sản xuất thuốc không vô trùng nhóm penicillin: Viên nang cứng, viên nén, viên nén bao phim, thuốc bột. Công suất thiết kế 250 triệu đơn vị/ năm. Dạng sản phẩm sản xuất của nhà máy: Viên nang cứng Viên nén, Viên nén bao phim Sản phẩm dạng gói

Nhóm sản phẩm: nhóm Penicillin

Chất lượng SP: dược điển EP, USP, BP

Sản phẩm thuốc bột pha tiêm Imextoxim 1g là sản phẩm Imexpharm đầu tiên nhận MA Châu Âu. Đánh dấu sự khởi đầu cho việc xuất khẩu sản phẩm thuốc chất lượng cao sang thị trường Châu Âu vốn đòi hỏi khắc khe về mặt chất lượng.

EU-GMP certification Imexpharm became the first domestic pharmaceutical company to obtain simultaneously the EU-GMP certification from the Ministry of Health of Spain (ICH group)

THE MINISTRY OF HEALTH OF SPAIN GRANTED THE CERTIFICATION OF EU-GMP SIMULTANEOUSLY FOR 03 PRODUCTION LINES OF THE HIGH-TECH BETALACTAM PLANT OF IMEXPHARM IN BINH DUONG The year 2016 became one of the most memorable milestone in the history of development and determination of investing in the core capability of “Product quality” when Imexpharm became the first domestic pharmaceutical company to obtain simultaneously the EU-GMP certification from the Ministry of Health of Spain (ICH group) for 03 production lines in the High-tech Betalactam Plant in Binh Duong being the Cephalosporin tablets and injection production lines and Penicillin injection production lines in September 2016.

With the advantage of costs of production and being one of the rare domestic enterprises to first obtain EU-GMP, PIC/SGMP certification, Imexpharm expected to develop its market shares well in the middle term and long term on all 3 channels: OTC, ETC and exports, with the target ratio to 2020 of 60%:30%:10% respectively.

IMPLEMENTATION OF THE PROJECT OF THE HIGH-TECH ANTIBIOTICS PLANT IN VINH LOC On 21 May 2016, the Board of Directors of Imexpharm Corporation approved the implementation of additional investment in the project of the High-tech Antibiotics Plant in Vinh Loc under EU-GMP standard as per Resolution 23/NQHDQT-IMEX, with the projected investment capital being 180 billion VND. The intention regarding the investment in this plant had been planned by the Leadership of Imexpharm several years ago. The high-tech antibiotics plant in Vinh Loc will be soon completed and commissioned by the end of 2018, an investment expected to yield short-term benefits in order to diversify EU-GMP-certified product lines, as well as to ease pressure on the Non-Betalatam Plant in Cao Lanh City which has been overloaded in the face of general pressure on growth.

Construction of Hi-tech factory in Binh Duong according to EU-GMP standards

Issuing separate stock for strategic partners, like Pha No Pharmaceutical Joint Stock Company to raise the total charter capital to VND 289,426,460,000. Launching construction of the high-tech factory in Binh Duong, following EU-GMP standards, with new products launched onto the market and the expected investment capital of VND 300-350 billion, taken from the owner’s equity.

263,114,860,000 VND  was the charter capital in 2014

The Corporation continued implementing training, rotating staff, human resource changes and company restructuring under BSC. Imexpharm issued shares to increase charter capital to 263,114,860,000 VND from surplus capital and the ESOP employee share program. The company upgraded its Cephalosporin and penicillin factories in Binh Duong to EU-GMP standard; with an estimated budget of 50 billion VND.

Enzymatic technology for antibiotic products

The completion and opening of the Corporate Head Office Building, successful deployment of SAP-ERP Project, and deployment of the BSC project for restructuring the company, Re-approval GMPWHO for all factories, and approval WHO-GMP for the Injectable Penicillin factory in Binh Duong. Using materials produced by enzymatic technology of the Spanish DSM Group for well-known antibiotic products, such as pms-CLAMINAT, pms-PHARMOX, pms-OPXIL and pms-IMEDROXIL. Products, which are produced with this technology, are safe for public health and friendly to the environment.

167,058,100,000 VND was the charter capital in 2012

Launched SAP-ERP Project. Imexpharm became the first pharmaceutical company to deploy ERP projects across all 8 modules. Completed 10% bonus shares on charter capital, which was increased to 167,058,100,000 VND by drawing from capital surplus.

152,145,000,000 VND charter capital by 2011

In March - 2011, Novartis Group - Switzerland evaluated Binh Duong Cephalosporin factory to meet the stringent production standards of this partner.

The Corporation successfully issued shares to increase the charter capital to 152.145 billion VND.

June - 2011: Started construction of the injectable Penicillin factory at the Vietnam – Singapore II Industrial Park in Binh Duong. This factory applies European technologies and standards to produce powdered and injectable penicillin. The charter capital was increased to 50 billion VND from capital surplus

July - 2011: Started construction of a new Head Office at Cao Lanh City, Dong Thap. This project provided a completely new look, a physical representation of Imexpharm’s growth in the Mekong Delta Region and nationwide. Capital investment was 28 billion VND.

December - 2011: Established Binh Tan Sales Branch in Ho Chi Minh City to implement direct distribution of Imexpharm in Ho Chi Minh City area without intermediary distributors.

Total investment of 113 billion VND

Cephalosporin Factory (in Vietnam - Singapore II Industrial Park, Binh Duong Province) officially begins operation in September, with a total investment of 113 billion VND. This factory applies European technologies and standards to produce oral and injectable powder drugs - a new generation of cephalosporin. 2010 also saw the re-evaluation WHO GMP factory system, GSP-WHO warehouse system, and the first year evaluation of GMPWHO for the Binh Duong factory.

130 products have been produced

Imexpharm signed a joint venture production contract with Pharma Science - Canada. Both parties agreed on the coproduction of 130 products, including 92 with registration codes and 86 marketed products.

Charter capital was increased to 116,598,200,000 VND

Successfully demonstrated “bioequivalence” of Imeclor Antibiotics 125 mg (containing Cefaclor). Charter capital was increased to 116,598,200,000 VND from the payment of dividends and issuing more dividends.

The 1st VN's pharmaceutical company was approved by the State Securities Commission to list shares on the Ho Chi Minh Stock Exchange.

Charter capital was increased to 84 billion VND from issuing 20% bonus shares on charter capital, taken from the investment development fund. Imexpharm was the first pharmaceutical company to get approval from the State Securities Committee to list stock on the Ho Chi Minh City Stock Exchange (HOSE) starting December 4, 2006 under Decision No.76/UBCK

GPNY using the stock code ‘IMP.’ Invested and upgraded two factories, Betalactam and Non Betalactam, to satisfy GMP-WHO Standard (Good Manufacturing Practices), upgraded the laboratory to satisfy GLP-WHO Standard (Good Laboratory Practices), and upgraded the storage system to satisfy GSP -WHO Standard (Good Storage Practices).

Awarded a certificate by the National Commission for Economic Cooperation

Charter capital was increased to 64 billion VND by offering shares to strategic investors.

22 billion VND was the charter capital

Imexpharm became the first equitized pharmaceutical corporation ‘Imexpharm Pharmaceutical JSC’ under Decision No.907/QDTg dated July 25, 2001 with charter capital of 22 billion VND.

The 1st VN's pharmaceutical to produce for international corporations

Imexpharm looked to Europe in search of a new growth path, which led Imexpharm to become the first pharmaceutical company in Vietnam to perform concession production for large European corporations (Biochemie).

The 1st Company produce medicine under ASIAN- GMP standard in Vietnam

Imexpharm became the first Pharmaceutical Company in Vietnam to meet the Good Manufacturing Practices standard (GMP ASEAN)

150 billion VND in annual revenue

The Dong Thap People’s Committee established Dong Thap Pharmaceutical Company with Decision No. 120/QDTL. From this day, the company was built in the direction of sustainable development. The latest machinery equipment was installed and the higher qualified staff was recruited for the further development. There were about 200 people in staff and the annual revenue reached over 150 billion VND.

30 billion VND - the company annual revenue

The precursor of Imexpharm, Dong Thap Pharmaceutical United Enterprise, was founded in September, according to Decision no.284/Tccq dated September 28, 1983 by the Dong Thap Department of Health. The staff totaled approximately 70 people, about ten kinds of products being produced manually. The company had annual revenue of about 30 billion VND